Biomarker Testing in Ovarian Cancer

In ovarian cancer, treatment selection for platinum resistant disease is increasingly shaped by biomarkers, prior toxicity, and access to targeted therapy. The faculty review how folate receptor alpha testing has become an important part of clinical decision making because it can identify candidates for mirvetuximab soravtansine and help distinguish patients who may benefit from a more biomarker driven approach. Practical considerations are emphasized throughout, including the value of in house testing, faster turnaround time, and the challenge of fitting new therapies into an already crowded treatment landscape. Broader molecular workup remains essential as well, with discussion of germline and somatic testing, homologous recombination deficiency, and other features that inform treatment strategy across the disease course. Rather than treating a single biomarker as the whole story, the faculty frame targeted therapy as one part of a broader ovarian cancer management plan. The overall message is that precision treatment is becoming more feasible, but it still requires careful coordination of testing, timing, and supportive care.